Nurix Therapeutics (NASDAQ:NRIX) Trading Up 6.7%

Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Free Report)’s stock price was up 6.7% during mid-day trading on Wednesday . The stock traded as high as $16.31 and last traded at $15.95. Approximately 99,151 shares traded hands during trading, a decline of 89% from the average daily volume of 917,055 shares. The stock had previously closed at $14.95.

Analyst Ratings Changes

Several brokerages have issued reports on NRIX. Robert W. Baird lifted their price target on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research note on Thursday, April 11th. Morgan Stanley lifted their price target on Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Royal Bank of Canada lifted their price target on Nurix Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a research note on Thursday, April 11th. HC Wainwright decreased their price objective on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $21.88.

Read Our Latest Research Report on NRIX

Nurix Therapeutics Trading Up 6.4 %

The company has a market cap of $781.50 million, a PE ratio of -6.14 and a beta of 2.10. The firm has a 50 day moving average of $14.06 and a two-hundred day moving average of $10.44.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last issued its earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.04. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. The business had revenue of $16.59 million for the quarter, compared to the consensus estimate of $14.58 million. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -3.15 EPS for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,812 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $10.02, for a total transaction of $68,256.24. Following the sale, the chief financial officer now directly owns 68,333 shares in the company, valued at approximately $684,696.66. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 13,705 shares of company stock worth $154,012. Insiders own 9.80% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC raised its holdings in Nurix Therapeutics by 23.2% in the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock worth $32,972,000 after purchasing an additional 601,952 shares during the period. Vanguard Group Inc. raised its holdings in Nurix Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 2,714,845 shares of the company’s stock valued at $21,339,000 after acquiring an additional 22,804 shares during the period. Affinity Asset Advisors LLC raised its holdings in Nurix Therapeutics by 17.4% during the first quarter. Affinity Asset Advisors LLC now owns 810,253 shares of the company’s stock valued at $11,911,000 after acquiring an additional 120,141 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Nurix Therapeutics by 9.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 622,297 shares of the company’s stock valued at $6,422,000 after acquiring an additional 53,721 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Nurix Therapeutics by 41.6% during the fourth quarter. Wellington Management Group LLP now owns 205,324 shares of the company’s stock valued at $2,119,000 after acquiring an additional 60,271 shares during the period.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Stories

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.